Ultragenyx Pharmaceu (RARE)

$25.02 +0.11 (0.44%)
Market Cap 2.45B
Revenue (ttm) 673.00M
Net Income (ttm) -575.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -85.44%
Debt to Equity Ratio 0.00
Volume 2,085,700
Avg Vol 2,311,052
Day's Range N/A - N/A
Shares Out 98.49M
Stochastic %K 21%
Beta 0.31
Analysts Strong Sell
Price Target $52.65

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevi...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 483 8800
Address:
60 Leveroni Court, Novato, United States
StocktwitsNews
StocktwitsNews Aug. 3 at 9:26 PM
MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading $MRNA $LNTH $RARE $BMY $CAPR https://stocktwits.com/news/equity/markets/mrna-lnth-bmy-capr-rare-stocks-in-focus-these-fda-decisions-could-shape-august-trading/cZoTYS7RJ30
1 · Reply
Merlintrader
Merlintrader Aug. 2 at 3:38 PM
The Top Ten Biotech Stocks Right Now — updated for August with upcoming catalysts, clinical readouts, cash runway and key risks. Four names in focus: $RARE $PHVS $SLS $TLX Full ranked watchlist: https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
1 · Reply
Astrobro
Astrobro Jul. 31 at 5:27 PM
$RARE entering here. expecting approval in about 6 weeks.
1 · Reply
lonelywarrior
lonelywarrior Jul. 31 at 2:52 PM
$RARE For now it's moving with XBI - not a big deal as volume is low - only 187,922 by 10:51 AM
0 · Reply
Yashinvest
Yashinvest Jul. 31 at 7:25 AM
$RARE Weekly chart, potential to double
1 · Reply
lonelywarrior
lonelywarrior Jul. 30 at 6:45 PM
$RARE Low volume, but in line with XBI. Should see some volume and upside into PDUFA.
0 · Reply
inquisitive30
inquisitive30 Jul. 30 at 4:14 PM
$RARE algorithm primed to buy the minute of a form with no context. Cool Black Rock has had shares
0 · Reply
FDALens
FDALens Jul. 30 at 12:33 AM
$BMY $GILD $IONS $RARE $REPL good luck 🍀
0 · Reply
BioAlphaSignals
BioAlphaSignals Jul. 29 at 11:48 PM
4/ $RARE — Aug 23, 2026 PDUFA for DTX401 AAV gene therapy in glycogen storage disease type Ia. Thesis: rare-disease gene-therapy read-through; if approved, it targets the underlying cause of GSDIa vs chronic dietary management.
0 · Reply
BioAlphaSignals
BioAlphaSignals Jul. 29 at 11:47 PM
1/ Biotech FDA catalysts I’m watching over the next ~60 days. Not investment advice — just a sourced watchlist. PDUFA dates can move, and binary FDA events can gap hard both ways. Sources are company IR/news releases. $REPL $BMY $RARE $GILD $IONS
1 · Reply
Latest News on RARE
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

Jul 28, 2026, 4:05 PM EDT - 6 days ago

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 24, 2026, 4:30 PM EDT - 10 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)

Jul 15, 2026, 11:33 AM EDT - 19 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx price target raised to $30 from $26 at Wedbush

2026-07-13T12:10:54.000Z - 21 days ago

Ultragenyx price target raised to $30 from $26 at Wedbush

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

Jul 8, 2026, 9:08 AM EDT - 26 days ago

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

Ultragenyx price target raised to $40 from $35 at RBC Capital

2026-07-07T11:30:27.000Z - 27 days ago

Ultragenyx price target raised to $40 from $35 at RBC Capital

Ultragenyx Pharmaceutical Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 4:00 PM EDT - 7 weeks ago

Ultragenyx Pharmaceutical Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Jun 3, 2026, 4:30 PM EDT - 2 months ago

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald

2026-05-21T11:16:33.000Z - 2 months ago

Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald

Ultragenyx Pharmaceutical Transcript: AGM 2026

May 14, 2026, 11:30 AM EDT - 2 months ago

Ultragenyx Pharmaceutical Transcript: AGM 2026

Ultragenyx Pharmaceutical Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 5:20 PM EDT - 2 months ago

Ultragenyx Pharmaceutical Transcript: Bank of America Global Healthcare Conference 2026

Ultragenyx price target lowered to $33 from $34 at Evercore ISI

2026-05-11T16:15:56.000Z - 3 months ago

Ultragenyx price target lowered to $33 from $34 at Evercore ISI

Ultragenyx price target lowered to $26 from $27 at Wedbush

2026-05-08T13:52:56.000Z - 3 months ago

Ultragenyx price target lowered to $26 from $27 at Wedbush

Ultragenyx price target lowered to $43 from $52 at Guggenheim

2026-05-08T13:31:39.000Z - 3 months ago

Ultragenyx price target lowered to $43 from $52 at Guggenheim

Rare disease families find roadmap to drug development at bootcamps.

May 7, 2026, 4:00 PM EDT - 3 months ago

Rare disease families find roadmap to drug development at bootcamps.

Rare disease families find roadmap to drug development at bootcamps

May 7, 2026, 6:30 AM EDT - 3 months ago

Rare disease families find roadmap to drug development at bootcamps

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

May 6, 2026, 4:30 PM EDT - 3 months ago

Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference

Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q1 2026

Ultragenyx Pharmaceutical Earnings release: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

Ultragenyx Pharmaceutical Earnings release: Q1 2026

Ultragenyx Pharmaceutical Quarterly report: Q1 2026

May 5, 2026, 5:00 PM EDT - 3 months ago

Ultragenyx Pharmaceutical Quarterly report: Q1 2026

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

May 5, 2026, 4:01 PM EDT - 3 months ago

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Slides: Corporate presentation

May 5, 2026, 7:00 AM EDT - 3 months ago

Ultragenyx Pharmaceutical Slides: Corporate presentation

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Apr 29, 2026, 8:00 AM EDT - 3 months ago

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

Ultragenyx price target lowered to $43 from $44 at Barclays

2026-04-29T09:45:53.000Z - 3 months ago

Ultragenyx price target lowered to $43 from $44 at Barclays

Ultragenyx price target raised to $67 from $50 at Morgan Stanley

2026-04-16T12:35:15.000Z - 3 months ago

Ultragenyx price target raised to $67 from $50 at Morgan Stanley

DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

Apr 3, 2026, 9:43 AM EDT - 4 months ago

DEADLINE NEXT WEEK: Berger Montague Advises Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investors to Contact the Firm Before April 6, 2026

Ultragenyx UX111 AAV9 biologics license application accepted for FDA review

2026-04-02T13:06:11.000Z - 4 months ago

Ultragenyx UX111 AAV9 biologics license application accepted for FDA review

Ultragenyx announces FDA clearance of UX016 investigational new drug application

2026-03-30T13:27:59.000Z - 4 months ago

Ultragenyx announces FDA clearance of UX016 investigational new drug application

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Mar 30, 2026, 8:30 AM EDT - 4 months ago

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 4 months ago

Ultragenyx Pharmaceutical Proxy statement: Proxy filing

Ultragenyx downgraded to Neutral from Buy at Goldman Sachs

2026-03-24T08:35:19.000Z - 4 months ago

Ultragenyx downgraded to Neutral from Buy at Goldman Sachs

Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims

2026-03-18T15:57:48.000Z - 4 months ago

Ultragenyx Facing Shareholder Lawsuit over Brittle Bone Disease Drug Claims

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Mar 12, 2026, 8:47 AM EDT - 5 months ago

Ultragenyx's gene therapy helps control ammonia levels in late-stage study

Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 11:00 AM EDT - 5 months ago

Ultragenyx Pharmaceutical Transcript: Leerink Global Healthcare Conference 2026

Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 12:00 PM EDT - 5 months ago

Ultragenyx Pharmaceutical Transcript: Barclays 28th Annual Global Healthcare Conference

Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:50 PM EST - 5 months ago

Ultragenyx Pharmaceutical Transcript: TD Cowen 46th Annual Health Care Conference

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Feb 24, 2026, 9:11 AM EST - 5 months ago

Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Ultragenyx to Participate at Investor Conferences in March

Feb 23, 2026, 4:30 PM EST - 5 months ago

Ultragenyx to Participate at Investor Conferences in March

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Feb 23, 2026, 8:30 AM EST - 5 months ago

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Feb 18, 2026, 2:07 PM EST - 5 months ago

Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE

Ultragenyx Pharmaceutical Earnings Call Transcript: Q4 2025

Feb 12, 2026, 5:00 PM EST - 6 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q4 2025

Ultragenyx Pharmaceutical Annual report: Q4 2025

Feb 12, 2026, 5:00 PM EST - 6 months ago

Ultragenyx Pharmaceutical Annual report: Q4 2025

Ultragenyx Pharmaceutical Earnings release: Q4 2025

Feb 12, 2026, 5:00 PM EST - 6 months ago

Ultragenyx Pharmaceutical Earnings release: Q4 2025

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Feb 12, 2026, 4:01 PM EST - 6 months ago

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Slides: Corporate presentation

Feb 12, 2026, 7:00 AM EST - 6 months ago

Ultragenyx Pharmaceutical Slides: Corporate presentation

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Feb 9, 2026, 3:01 AM EST - 6 months ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Feb 3, 2026, 8:00 AM EST - 6 months ago

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Jan 30, 2026, 8:30 AM EST - 6 months ago

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Jan 23, 2026, 2:05 PM EST - 6 months ago

Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies

Ultragenyx Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 7 months ago

Ultragenyx Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 7 months ago

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

Ultragenyx Pharmaceutical Slides: Corporate presentation

Jan 10, 2026, 7:00 AM EST - 7 months ago

Ultragenyx Pharmaceutical Slides: Corporate presentation

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Dec 30, 2025, 4:05 PM EST - 7 months ago

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Dec 30, 2025, 2:24 PM EST - 7 months ago

Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

Dec 29, 2025, 1:05 PM EST - 7 months ago

These biotech stocks are getting hammered by shocking brittle-bone treatment study results

MREO

Ultragenyx's bone disease drug fails late-stage trials

Dec 29, 2025, 8:35 AM EST - 7 months ago

Ultragenyx's bone disease drug fails late-stage trials

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Dec 29, 2025, 8:30 AM EST - 7 months ago

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Ultragenyx Pharmaceutical Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 12:55 PM EST - 8 months ago

Ultragenyx Pharmaceutical Transcript: Evercore ISI 8th Annual HealthCONx Conference

Ultragenyx Pharmaceutical Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 3:15 PM EST - 8 months ago

Ultragenyx Pharmaceutical Transcript: Citi Annual Global Healthcare Conference 2025

Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2025

Nov 4, 2025, 5:00 PM EST - 9 months ago

Ultragenyx Pharmaceutical Earnings Call Transcript: Q3 2025

Ultragenyx Pharmaceutical Quarterly report: Q3 2025

Nov 4, 2025, 5:00 PM EST - 9 months ago

Ultragenyx Pharmaceutical Quarterly report: Q3 2025

Ultragenyx Pharmaceutical Earnings release: Q3 2025

Nov 4, 2025, 5:00 PM EST - 9 months ago

Ultragenyx Pharmaceutical Earnings release: Q3 2025

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Nov 4, 2025, 4:01 PM EST - 9 months ago

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Ultragenyx Pharmaceutical Slides: Corporate Presentation

Nov 3, 2025, 6:00 PM EST - 9 months ago

Ultragenyx Pharmaceutical Slides: Corporate Presentation

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Oct 28, 2025, 4:30 PM EDT - 9 months ago

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Sep 30, 2025, 4:05 PM EDT - 10 months ago

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Sep 8, 2025, 4:05 PM EDT - 11 months ago

Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)

Ultragenyx to Participate at Investor Conferences in September

Aug 29, 2025, 4:30 PM EDT - 1 year ago

Ultragenyx to Participate at Investor Conferences in September

StocktwitsNews
StocktwitsNews Aug. 3 at 9:26 PM
MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus — These FDA Decisions Could Shape August Trading $MRNA $LNTH $RARE $BMY $CAPR https://stocktwits.com/news/equity/markets/mrna-lnth-bmy-capr-rare-stocks-in-focus-these-fda-decisions-could-shape-august-trading/cZoTYS7RJ30
1 · Reply
Merlintrader
Merlintrader Aug. 2 at 3:38 PM
The Top Ten Biotech Stocks Right Now — updated for August with upcoming catalysts, clinical readouts, cash runway and key risks. Four names in focus: $RARE $PHVS $SLS $TLX Full ranked watchlist: https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
1 · Reply
Astrobro
Astrobro Jul. 31 at 5:27 PM
$RARE entering here. expecting approval in about 6 weeks.
1 · Reply
lonelywarrior
lonelywarrior Jul. 31 at 2:52 PM
$RARE For now it's moving with XBI - not a big deal as volume is low - only 187,922 by 10:51 AM
0 · Reply
Yashinvest
Yashinvest Jul. 31 at 7:25 AM
$RARE Weekly chart, potential to double
1 · Reply
lonelywarrior
lonelywarrior Jul. 30 at 6:45 PM
$RARE Low volume, but in line with XBI. Should see some volume and upside into PDUFA.
0 · Reply
inquisitive30
inquisitive30 Jul. 30 at 4:14 PM
$RARE algorithm primed to buy the minute of a form with no context. Cool Black Rock has had shares
0 · Reply
FDALens
FDALens Jul. 30 at 12:33 AM
$BMY $GILD $IONS $RARE $REPL good luck 🍀
0 · Reply
BioAlphaSignals
BioAlphaSignals Jul. 29 at 11:48 PM
4/ $RARE — Aug 23, 2026 PDUFA for DTX401 AAV gene therapy in glycogen storage disease type Ia. Thesis: rare-disease gene-therapy read-through; if approved, it targets the underlying cause of GSDIa vs chronic dietary management.
0 · Reply
BioAlphaSignals
BioAlphaSignals Jul. 29 at 11:47 PM
1/ Biotech FDA catalysts I’m watching over the next ~60 days. Not investment advice — just a sourced watchlist. PDUFA dates can move, and binary FDA events can gap hard both ways. Sources are company IR/news releases. $REPL $BMY $RARE $GILD $IONS
1 · Reply
inquisitive30
inquisitive30 Jul. 29 at 10:41 PM
$RARE
0 · Reply
inquisitive30
inquisitive30 Jul. 28 at 3:10 PM
$RARE
0 · Reply
lonelywarrior
lonelywarrior Jul. 28 at 2:14 PM
$RARE This price is a steal - driven by macro and XBI decline, nothing company-specific.
1 · Reply
fda_tracker
fda_tracker Jul. 27 at 3:36 PM
$RARE Phase 3 trial w/est Jul completion date NCT06617429: https://www.clinicaltrials.gov/study/NCT06617429 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
Merlintrader
Merlintrader Jul. 25 at 9:07 PM
$RARE $TENX $CAPR $PHVS The Top Ten Biotech Stocks Right Now https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
0 · Reply
OutperformGER
OutperformGER Jul. 25 at 3:47 PM
$MREO and $RARE Emil Kakkis 👇
0 · Reply
inquisitive30
inquisitive30 Jul. 24 at 2:45 PM
$RARE wake me up 🥱
0 · Reply
theoptionsplug
theoptionsplug Jul. 23 at 2:27 PM
$RARE received nearly $600K in October Call Orders! DMAs JUST GOLDEN CROSSED! Sitting on support of ~$27 GREAT long term buy!
0 · Reply
Merlintrader
Merlintrader Jul. 22 at 8:51 PM
$RARE $PHVS $EYPT $TENX
0 · Reply
Merlintrader
Merlintrader Jul. 21 at 8:32 PM
$RARE $PHVS $EYPT $TENX The Top Ten Biotech Stocks Right Now https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
0 · Reply
Filvul
Filvul Jul. 21 at 7:20 PM
$RARE
0 · Reply
OptionRunners
OptionRunners Jul. 21 at 3:44 PM
$RARE lots of bearish flow over the past month
1 · Reply